Tela Bio Inc (TELA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Tela Bio Inc stock (TELA) is currently trading at $0.69. Tela Bio Inc PS ratio (Price-to-Sales) is 0.44. Analyst consensus price target for TELA is $3.45. WallStSmart rates TELA as Sell.
- TELA PE ratio analysis and historical PE chart
- TELA PS ratio (Price-to-Sales) history and trend
- TELA intrinsic value — DCF, Graham Number, EPV models
- TELA stock price prediction 2025 2026 2027 2028 2029 2030
- TELA fair value vs current price
- TELA insider transactions and insider buying
- Is TELA undervalued or overvalued?
- Tela Bio Inc financial analysis — revenue, earnings, cash flow
- TELA Piotroski F-Score and Altman Z-Score
- TELA analyst price target and Smart Rating
Tela Bio Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Tela Bio Inc (TELA) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Tela Bio Inc (TELA) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
72.09% of shares held by major funds and institutions
Supporting Valuation Data
Tela Bio Inc (TELA) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 23.9x book value
Micro-cap company with very limited liquidity and high volatility
Modest revenue growth at 9.10%
Tela Bio Inc (TELA) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Institutional Own.. Valuation metrics including Price/Sales (0.44) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Book (23.89) suggest expensive pricing. Growth concerns include Revenue Growth at 9.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -676.00%, Operating Margin at -36.50%, Profit Margin at -50.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -676.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 9.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TELA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TELA's Price-to-Sales ratio of 0.44x sits near its historical average of 0.47x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 15% below its historical high of 0.52x set in Mar 2026, and 5% above its historical low of 0.42x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Tela Bio Inc (TELA) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Tela Bio Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 77M with 9% growth year-over-year. The company is currently unprofitable, posting a -50.6% profit margin.
Key Findings
The company is unprofitable with a -50.6% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Tela Bio Inc.
Bottom Line
Tela Bio Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Tela Bio Inc(TELA)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
TELA Bio, Inc., a medical technology company, focuses on the design, development and commercialization of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is headquartered in Malvern, Pennsylvania.